Indeed, parallels can be drawn with immunotherapeutic approaches currently being investigated in HPV-driven human cancers, such as checkpoint inhibition (PD-1/PD-L1, CTLA-4 blockade), therapeutic vaccines, and nanoparticle-mediated delivery of viral antigen targets [28,29]. Here, CTLA4 is linked to cancer.